In the November 2009 issue of Nature Reviews Clinical Oncology, the data for estimated survival at 3 years in patients who received rituximab maintenance therapy should have read 77%, not 55%.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2009.161
Rights and permissions
About this article
Cite this article
Cheson, B. Correction: The case against rituximab maintenance. Nat Rev Clin Oncol 6, 678 (2009). https://doi.org/10.1038/nrclinonc.2009.190
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.190
